ImageneBio, Inc. (IMA) research

ImageneBio, Inc.
ShareXLinkedInReddit
Sector
Healthcare
Industry
Biotechnology
Last price
$4.84
As of

ImageneBio, Inc. (IMA): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-05.

As of . Source: SEC EDGAR filings for IMA. Method and limitations.

SHARE THIS CARD

Share the IMA intelligence card

A branded snapshot of IMA: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion IMA intelligence card preview
Post to X
LIVE TERMINAL

See IMA live in the terminal

Track IMA's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live IMA terminal, free

Active signals for IMA

FREE, NO ACCOUNT

Every signal on IMA, as it fires

You are seeing 5 of 8 signals recorded on IMA since 2026-05-17.

The five above landed across 3 days. The other 3 were recorded on 1 other days. 4 of the 8 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in IMA (2026Q2)

Manager / securityMarket value% portfolioQoQ
RENAISSANCE TECHNOLOGIES LLCCUSIP 45175G207 · 2026Q2$513K0.00%,
CITADEL ADVISORS LLCCUSIP 45175G207 · 2026Q2$328K0.00%,
TWO SIGMA INVESTMENTS, LPCUSIP 45175G207 · 2026Q2$117K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, IMA

IMA mentioned in Kresmion daily briefs

IMA against its peers

IMA's operating margin of -6056.4% ranks in the 41st percentile of 10 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.

MetricIMAPeer medianPercentilen
Revenue FY800000 USD801228 USD5012
Operating margin-6056.4%-3047.9%4110
Net margin-5668.6%-351.5%2911
Return on equity-34.1%-99.3%8117

Peers (24): SER, HYPD, ELOX, EXOZ, XLO, AURX, CALC, INKT, HRTX, INMB, MCRB, ELTX, TIL, IBO, LONA, BOLD, IMMP, XBIT, TVGN, HOWL, DWTX, SPRO, RNTX, GOSS. Left out: HYFT (period gap). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (IMA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more IMA signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to IMAand get the insider, 13F, options, and confluence read in one view.

Open the live IMA terminal, free